Novartis has struck a front-loaded deal to buy Synnovation Therapeutics’ pan-mutant‑selective PI3Kα inhibitor for $2 billion, ...

Gilead has handed back a next-gen hepatitis B antiviral to Assembly Biosciences, while the two companies continue to partner ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

R1 Therapeutics is debuting with an oversubscribed $77.5 million series A financing aimed at advancing its first-in-class ...

Swiss pharma Roche is staying in lockstep with Eli Lilly, expanding its artificial intelligence offerings and Nvidia ...

JenaValve has secured the FDA’s approval for its minimally invasive heart implant, making it the first to claim a U.S. green ...

About a month after Pfizer CEO Albert Bourla, Ph.D., told investors that the Big Pharma’s pipeline pruning was mostly done, ...

One of the world’s largest hearing aid retailers plans to bring a top manufacturer under its roof in a major acquisition that ...

As Eli Lilly begins to take the next generation of obesity drugs to regulators this year, a lower-profile collaboration ...

Health authorities in the U.S. are continuing their move away from animal testing in drug development, with the FDA signaling ...

Astellas is pulling out of its $1.6 billion biobucks partnership with CytomX Therapeutics six years after the two companies set out to explore T-cell-engaging bispecifics for the treatment of solid ...

Genentech is halting development of an antibody for two rare genetic diseases after the candidate failed to boost muscle growth, raising questions about whether the molecule can preserve muscle in two ...